Key phase changes in the pharmaceutical pipeline

 

Thomson Scientific
September 2006

Thomson Scientific has launched a new line of free reports from Thomson Pharma SM. The Ones To Watch reviews recent phase changes in the pharmaceutical pipeline, bringing you expert insight into the five most promising drugs at each stage.

The Ones To Watch is compiled by the industry analysts behind Thomson Pharma, the essential pharmaceutical knowledge and news service. The first report, covering April to June 2006, reviews the five most promising drugs:

  • reaching the market — including Gardasil™ from Merck & Co (for cervical cancer) and Schwarz Pharma's Neupro® (for Parkinson's disease)
  • entering Phase III trials — including DG-031, originally developed by Bayer for asthma, but now licensed to deCode and in trials for myocardial infarction
  • entering Phase II trials — GTx's Ostarine, a potential treatment for bone loss and muscle wasting in elderly men and postmenopausal women is the first selective androgen receptor modulator to reach this stage of testing.
  • entering Phase I trials — Crucell and the University of Leicester (UK) have a H9N2-based avian influenza vaccine in trials

Download The Ones to Watch and register to receive free PDF copies of future reports.

Additional information

Download The Ones to Watch and register to receive free PDF copies of future reports.

Thomson Pharma

Was this article useful?

Sign up for our newsletter
so we can keep you up to date

Note for journalists

Looking for an expert source for your story?
Visit our Expert Directory